SEP 17, 2019 06:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

Post-translational modification enrichment and quantitation for precision medicine and drug development

SPONSORED BY: Cell Signaling Technology
C.E. CREDITS: P.A.C.E. CE | Florida CE
  • Professor of Translational OncoProteomics, Dept. Medical Oncology, and Head of the OncoProteomics Laboratory and Director of the Proteomics Core, Amsterdam University Medical Center
      Connie Jimenez is a biologist and proteome researcher who pioneered single cell neuropeptide profiling by mass spectrometry in the 1990s during her Ph.D. studies at the Vrije Universiteit in Amsterdam. She then performed post-doctoral neuroproteomics research at the University of California-San Francisco and Vrije Universiteit.
      In 2006, Dr. Jimenez founded the OncoProteomics Laboratory at Cancer Center Amsterdam to employ the power of mass spectrometry-based proteomics to study cancer ( Her lab's mission is to apply innovative mass spectrometry-based phosphoproteomics and data analysis to improve early diagnosis and treatment of cancer and neurodegenerative diseases. Label-free proteomics and dedicated data analysis strategies are employed to investigate extracellular proteins in in vitro and in vivo proximal fluids (urine, CSF, stool) to develop non-invasive biomarker applications, and intracellular phosphoproteins to enable patient stratification and response prediction. These approaches have been successfully applied in multiple collaborative projects in various cancers including colorectal, breast, lung, prostate, and pancreatic cancer, leukemia, and neurodegenerative diseases.
      Dr. Jimenez has authored over 140 peer-reviewed articles, 11 book chapters, and 8 articles in popular science and clinical journals. She is active in several international proteomics networks: founder and member of the Steering Committee of the Netherlands Proteomics Platform, general council member of the European Proteomics Association, co-chair of the Cancer Initiative of the Human Proteome Organization. Dr. Jimenez serves on the editorial boards of Journal of Proteomics, Molecular and Cellular Proteomics, Proteomics, and Clinical Proteomics.
    • Project Leader in Proteomics & Mass Spectrometry at Roche in Basel, Switzerland
        Manuel Tzouros has served as proteomics project leader at the Roche Innovation Center in Basel, Switzerland since 2011. Dr. Tzouros' primary responsibility is providing cutting-edge, mass spectrometry-based, proteomics support to collaborators originating from an array of disease areas including oncology, neuroscience, rare diseases, immunology, infectious diseases, and ophthalmology. His projects typically span early drug development phases, although clinical applications are increasing. Dr. Tzouros' major area of expertise encompasses the quantification of post-translational modifications, such as phosphorylation and ubiquitylation, which can be implicated in disease. This serves to address important questions related to target biology, drug effect, mode of action, and safety, as well as biomarker discovery. Prior to his current work at Roche, Dr. Tzouros performed post-doctoral research at Utrecht University in The Netherlands and at Roche in Basel, Switzerland.

      DATE:  September 17, 2019
      TIME:    6:00 am PDT, 9:00am EDT, 2:00pm BST, 3:00pm CEST
      Innovative mass spectrometry-based proteomics is a powerful tool for obtaining insights into disease-related cellular signaling pathways, biomarkers, and potential drug targets. This technology is being used to investigate phosphorylation of extracellular and intracellular proteins with the aim of improving early diagnosis and treatment of cancer and neurodegenerative diseases. In addition to phosphorylation studies, this technology can also be used to detect other PTMs including ubiquitylation. For example, E3 ubiquitin ligases represent a challenging, yet promising, class of proteins in drug discovery. In particular, combining the ligases with targeted protein degradation technology opens the door to developing new tools to study protein ubiquitinylation. To this end, the peptide K-ε-GG remnant affinity enrichment approach (PTMScan®) has been adapted for use with an automated liquid handling platform. This allows increased sensitivity and throughput while decreasing sample-to-sample variability in quantitative experiments. This approach has been successfully applied to the identification of downstream substrate protein candidates of disease-relevant E3 ubiquitin ligases. This webinar considers study design for label-free analysis, enrichment strategies, and data analysis involving both preclinical models and clinical samples with a focus on cancer.
      During this webinar, participants will:
      • Gain an understanding of the use of pTyr and global affinity enrichment workflows for label-free phosphoproteomics
      • Learn about single-sample integrative data analysis workflow (INKA) for kinase activity scoring
      • Consider an automated workflow for modified peptide affinity enrichment using PTM antibodies, its application for the exploration of E3 ligase substrates, and their potential use as target engagement biomarkers


      Webinars will be available for unlimited on-demand viewing after live event.

      LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

      Show Resources
      Show Resources
      Event Countdown
      • 0 Days
      • 0 Hours
      • 0 Minutes
      • 0 Seconds
      Connect with us